China has 4,804 new drug candidates under development, second only to the US at 5,268, according to data provider PharmCube.

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

Against a backdrop of rising U.S.-China geopolitical tensions, there are signs of growing dealmaking activity between Western ...

Pharmaron, a Chinese biotech firm, is currently using hundreds of thousands of taxpayer dollars to test pharmaceuticals on up ...

Merck's (NYSE:MRK) recent acquisition of rights to Chinese biotech LaNova Medicines' cancer candidate LM-299 in a deal worth up to $3.3B underscores Big Pharma's appetite for best-in-class assets ...

This has all had negative effects on American companies, but Chinese interference in biotechnology also presents national security risks for the United States as a whole. The Senate has an ...

The China-US trade war has spread to the biotech industry, as the US BIOSECURE Act looks to dampen Chinese influence on a range of services, including contract manufacturing. Ben Hargreaves ...

The biotech plans to file a New Drug Application for olverembatinib in 2026 ... Robert Califf to flag ethical concerns regarding the “alarming practice” of some U.S. companies that work with the ...

The Chinese biotech industry has grown rapidly to become a major hub of research. However, as US-China trade relations continue to deteriorate, Ben Hargreaves asks whether this could stunt ...